Colon cancer screening will be much easier with accurate new blood test

Colon cancer remains a formidable challenge in the realm of public health, with its detection and early intervention being crucial for effective treatment. Thankfully, medical science is making breakthroughs in both areas.

Scientists revealed today that a new blood test demonstrates an 83% success rate in identifying colon cancer among individuals of average risk who show no symptoms. This level of accuracy is on par with the existing at-home stool tests, marking a significant stride toward more accessible and convenient cancer screening methods.

Early detection: The blood test breakthrough

Developed and tested within the scope of the ECLIPSE study — a comprehensive clinical trial led by Guardant Health involving nearly 8,000 participants aged 45 to 84 — the Shield blood test compares favorably to the colonoscopy, the current pinnacle of colorectal cancer screening.

The test operates by detecting signals of colorectal cancer through circulating tumor DNA (ctDNA) present in the blood, a method also employed in liquid biopsies for monitoring cancer recurrence.

Dr. William M. Grady, MD, a leading gastroenterologist at the Fred Hutchinson Cancer Center and the corresponding author of the study, emphasized the significance of these findings.

“The results of the study are a promising step toward developing more convenient tools to detect colorectal cancer early while it is more easily treated,” Dr. Grady stated. “The test, which has an accuracy rate for colon cancer detection similar to stool tests used for early detection of cancer, could offer an alternative for patients who may otherwise decline current screening options,” he explained further.

Importance of screening for colon cancer

However, the test showed varying sensitivity, with its detection capabilities being stronger for colorectal cancers, including those at early stages, and less so for advanced precancerous lesions.

Despite this, Dr. Grady reaffirms the test’s utility, especially given its similar sensitivity to that of stool-based tests and its potential role in complementing the more accurate, yet invasive, colonoscopy screenings.

Highlighting the broader implications of this innovation, Dr. Grady addressed the underutilization of existing screening tests, with only 50% to 60% of eligible individuals partaking in them.

“Getting people to be screened for cancer works best when we offer them screening options and then let them choose what works best for them,” he remarked, underscoring the importance of increasing screening accessibility and options.

Battling the silent predator

The urgency of improving colorectal cancer screening rates is underscored by its status as the second leading cause of cancer deaths in the U.S., with an estimated 53,010 fatalities expected in 2024. This, according to the American Cancer Society.

Alarmingly, while older adults have seen a decline in mortality rates, there has been a consistent annual increase in cases among individuals under 55 since the mid-2000s.

Current guidelines recommend that average-risk individuals begin regular screening at age 45, a recommendation that becomes increasingly pertinent as the incidence among younger populations continues to rise.

Dr. Grady also highlighted the particular significance of this advancement for younger demographics. “We continue to see younger people getting colorectal cancer and it’s now the third most common cancer for people under the age of 50,” Grady concluded.

Accuracy, availability and the future

The availability of a blood-based test could facilitate more widespread screening during routine doctor visits, potentially increasing the rate of early detection and successful treatment outcomes.

In summary, the development of a blood test for colorectal cancer screening marks a significant leap forward in the battle against a disease that claims thousands of lives annually.

By offering an 83% success rate in detecting colon cancers among asymptomatic, average-risk individuals, this innovative approach promises to enhance early detection rates, improve patient outcomes, and offer a convenient alternative to traditional screening methods.

As the medical community and patients alike embrace these advancements, the future of cancer screening looks brighter, paving the way for more lives saved and a decrease in cancer-related mortality. With ongoing research and widespread implementation, this blood test stands to revolutionize how we approach colorectal cancer prevention and care.

More about colon cancer

As discussed above, colon cancer poses a significant risk to individuals worldwide, quickly becoming one of the most prominent cancer diagnoses in the world.

By delving into its causes, symptoms, and the paramount importance of early detection, we can empower ourselves with the knowledge to combat this silent threat effectively.

This deadly disease originates in the large intestine or colon, which is the final part of the digestive tract. Typically starting as small, benign clumps of cells called polyps, colon cancer develops when these polyps undergo mutations in their DNA, growing and evolving into malignant tumors over time.

Factors increasing the risk of colon cancer include age, a high-fat diet, a history of polyps, inflammatory intestinal conditions, and genetics.

Warning signs and early detection

Early stages of colon cancer seldom manifest with symptoms, making its early detection challenging yet crucial. As the condition progresses, symptoms may include changes in bowel habits, blood in the stool, persistent abdominal discomfort, unexplained weight loss, and fatigue. Noticing these warning signs early can be a lifesaver, urging immediate medical consultation.

Early detection of colon cancer significantly enhances treatment success rates. Screening methods like colonoscopies allow doctors to identify and remove polyps before they transform into cancer.

The introduction of non-invasive tests, such as the promising blood test for colorectal cancer, provides additional, accessible options for early detection, aiming to increase screening uptake among the eligible population.

Ending colon cancer with preventive measures

Preventive measures can markedly reduce the risk of developing colon cancer. Maintaining a healthy diet rich in fruits, vegetables, and whole grains, regular exercise, moderating alcohol consumption, avoiding tobacco, and adhering to recommended screening schedules are effective strategies in preventing colon cancer. Moreover, understanding and managing personal risk factors play a crucial role in prevention.

In the fight against colon cancer, knowledge, vigilance, and proactive prevention are our best defenses. With advances in screening techniques and a growing awareness of the importance of early detection, we have the tools to challenge and ultimately reduce the impact of this disease.

By making informed lifestyle choices and participating in regular screenings, individuals can take significant steps toward safeguarding their health against colon cancer, moving closer to a future where this disease no longer poses a major health threat.

The full study was published in the New England Journal of Medicine.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–